EDP Biotech pitches last week, participating in two upcoming events in November

With “LSTCON,” the annual conference of Life Science Tennessee, beginning today in a virtual environment, it’s a good time to provide an update on one of the Knoxville-based companies in the sector.

Eric Mayer, Chief Executive Officer of EDP Biotech Corporation, alerted us to several important events for the company. One was last week during “Startup Week Chattanooga,” the other two are upcoming.

“EDP was honored to participate in CO.LAB’s ‘HealthTech Demo Day and Investor Panel’ last week,” Mayer said. “After spending the summer in their accelerator alongside other great tech entrepreneurs, we were able to demonstrate our ‘go-to-market strategy’ for both COVID and ColoPlexTM testing, highlighting our recent company progress and future potential. Insights from the panelists Rebekah Sharpe and Marcus Whitney will help EDP Biotech improve as we continue to grow the company.”

The other two upcoming events are the: (1) “New Orleans Health Innovators” (NOLAHI) forum November 18 that was postponed earlier in the year; and (2) 2020 American Diabetes Association’s (ADA) “HealthTech Showcase” where EDP Biotech will be an exhibitor November 5 and 6.  

“We are honored to be selected as a panelist speaking at the NOLAHI discussion about inequities in healthcare,” Mayer said. “One of EDP’s core missions is to develop cost-effective diagnostics that detect disease early, when patient outcomes are the best. It is important to us that early detection products are equally accessible to everyone.

As far as the ADA Showcase, Mayer explained that exhibiting the company’s technology provides an important strategic opportunity. “As EDP Biotech expands our menu of tests and geographic reach, we desire to use our underlying ‘multiplex’ technology to address other chronic diseases and complement the important work conducted by the American Diabetes Association,” he said.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.